Brief communication: immunogenicity of measles vaccine when co-administered with 10-valent pneumococcal conjugate vaccine

Zheng Quan Toh, Beth Temple, Tran Ngoc Huu, Vo Thi Trang Dai, Nguyen Trong Toan, Doan Y. Uyen, Kathryn Bright, Lien Anh Ha Do, E. Kim Mulholland and Paul V. Licciardi

INTRODUCTION

Measles is one of the most highly contagious human pathogens, accounting for significant morbidity and mortality worldwide, with the highest burden in low- and lower-middle-income countries. Routine measles vaccination for children, combined with mass immunisation campaigns in countries with low routine coverage, are key public health strategies to reduce global measles deaths. However, the global vaccine coverage of two-dose measles vaccine (MV) schedules (85 and 67% for first and second dose, respectively) are well short of the recommended 95% coverage needed to prevent outbreaks. The recent global measles outbreak has claimed more than 140,000 lives, mostly among young children in the poorest countries. In the first three months of 2019, provisional data based on monthly reports to the World Health Organization (WHO; as of April 2019) showed an almost 300% increase in the number of measles cases reported globally compared with the same period in 2018. Such outbreaks highlight the importance of immunisation and the maintenance of high MV coverage in the country.

The Expanded Programme on Immunization (EPI) was established in 1974 to improve vaccination rates against measles, diphtheria, pertussis, tetanus, poliomyelitis and tuberculosis. Since then many other vaccines have been added to the EPI schedule, including Hepatitis B, yellow fever and Haemophilus influenzae (Hib) conjugate vaccine, and more recently pneumococcal conjugate vaccines (PCV) and rotavirus vaccine. Some of these vaccines are given simultaneously (co-administered) to alleviate logistical constraints related to vaccine delivery and also improve vaccine coverage. The exact EPI schedule varies by country.

PCV protects against Streptococcus pneumoniae infection, a leading cause of pneumonia and serious invasive diseases in children under 5 years. Two licensed PCVs, 10-valent (PCV10, Synflorix®, GSK) and 13-valent PCV (PCV13, Prevenar-13/Prevenar-13; Pfizer), are available and are demonstrated to be safe and effective in preventing vaccine-type pneumococcal diseases. While these vaccines are in use in many regions, PCV introduction in Asia has been slow, in part due to the high vaccine cost, and also a lack of local or regional data on the effect of PCV for the government to consider PCV introduction. This is a priority as Asia, in particular the South East Asia region has one of the highest burden of pneumococcal disease globally with approximately 4.4 million cases occurring each year. One important consideration for countries planning to introduce PCV is whether it will interfere with the immunogenicity of other EPI vaccines. WHO recommends PCV to be given as a three-dose schedule, either as a two-dose primary series followed by a booster dose at 9–18 months (2 + 1) or as a three-dose primary series without a booster dose (3 + 0), for maximum efficacy. These schedules coincide with existing EPI vaccines and so it is necessary to ensure that their addition does not interfere with the immunogenicity and protection of any co-administered vaccines.

In Vietnam, measles vaccination is given as two-dose schedule under the EPI; MV (A1K-C strain, POLYVAC, Vietnam) at 9 months of age and measles–rubella (MR) combination vaccine at 18 months of age. As a booster dose of PCV may also be given at 9 months of age, it is important to determine whether this has any unintended consequences on MV immunogenicity. As a secondary analysis within a randomised, single-blind controlled trial of alternative PCV schedules in Vietnam (the Vietnam Pneumococcal Project), we investigated whether co-administration of PCV10 with MV at 9 months of age interferes with the immunogenicity of MV.

RESULTS AND DISCUSSION

Blood samples were collected at 10 months of age, from 144 participants who received both MV and PCV10 and from 133 participants who received MV alone at 9 months of age. The majority of participants in both groups were seropositive for measles antibody response; 142 (98.6%, 95% CI: 95.1–99.8%) in the MV-PCV10 group and 126 (94.7%, 95% CI: 89.5–97.9%) in the MV-only group (Fig. 1a). Both groups had similar measles IgG geometric mean concentrations (GMCs) [GMC 95% CI: MV-PCV10: 131.4, 120 AU/mL (105.2–136.9) MV-only: 111.8 AU/mL (95.2–131.4), P = 0.502] (Fig. 1b).

This is the first study in Asia to evaluate the co-administration of PCV and MV. Our data demonstrate that co-administration of
The administration of PCV10 with a tetravalent vaccine containing MV are limited, particularly for Asian countries. A multi-site trial in Europe examined the co-administration of PCV and MV. The seroconversion rates for measles were over 95% CI. GMC geometric mean concentrations, CI confidence interval.

In conclusion, in line with other studies, we have demonstrated a high measles seroconversion rate among children who received both PCV10 and MV. Our results therefore support the co-administration of PCV10 and MV at 9 months of age. These findings are most relevant for LMICs in Asia that are considering PCV introduction.

**METHODS**

Study design and participants

Two groups within the Vietnam Pneumococcal Project (ClinicalTrials.gov, number NCT01953510) received PCV10 in either a 3 + 1 schedule (at 2, 3, 4 and 9 months of age), or a 3 + 0 schedule (at 2, 3 and 4 months of age). Both groups received a first dose of MV at 9 months of age. Blood samples were collected 4 weeks post-MV. Details of the study design have been published previously. All relevant ethical regulations for work with human participants have been adhered; ethical approval has been obtained from the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research (EC00153) and the Vietnam Ministry of Health Ethics Committee and written informed consent from the parent/legal guardian were obtained.

Measurement of measles IgG response

The MV IgG response was examined using a commercial chemiluminescence immunoassay (Diasorin, USA). The assay detection range is 5–300 AU/mL. The criteria for classifying MV IgG responses were: negative: ≤13.5 AU/mL, equivocal: 13.5–16.5 AU/mL and positive: ≥16.5 AU/mL. The positive cut-off value equates to 175 mIU/mL based on the WHO Third International Standard for Anti-Measles; a titre of ≥120 mIU/mL by plaque reduction neutralisation test (PRNT) is considered protective. A previous
study comparing this commercial immunoassay with PRNT has found that samples in the equivocal range were >120 mIU/mL. The MV IgG GMCs were log-transformed and compared using Student’s t-test.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 7 April 2020; Accepted: 21 July 2020; Published online: 18 August 2020

REFERENCES
1. World Health Organization. Measles vaccines: WHO position paper, April 2017—recommendations. Vaccine 37, 219–222 (2019).
2. The World Health Organization. More than 140,000 Die from Measles as Cases Surge Worldwide (2019).
3. World Health Organization. New Measles Surveillance Data for 2019 (2019).
4. Wahl, B. et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob. Health 6, e744–e757 (2018).
5. The World Health Organization. Pneumococcus Vaccines Position Paper (2019).
6. Temple, B. et al. Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial. BMJ Open 8, e019795 (2018).
7. Chevallier, B. et al. Safety and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHID-CV) when coadministered with routine childhood vaccines. Pediatr. Infect. Dis. J. 28, S109–S118 (2009).
8. Lim, F. S. et al. A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHID-CV) co-administered with routine childhood vaccines in Singapore and Malaysia. BMC Infect. Dis. 14, 530 (2014).
9. van den Bergh, M. R. et al. Immunogenicity, safety and reactogenicity of a booster dose of the 10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine coadministered with DTPa-IPV-Hib in Dutch children: a randomised controlled trial. Pediatr. Infect. Dis. J. 35, e206–e219 (2016).
10. Vesikari, T. et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr. Infect. Dis. J. 29, e47–e56 (2010).
11. Oduotola, A. et al. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines—a phase II, randomised, observer-blind study in Gambian infants. Vaccine 37, 2586–2599 (2019).
12. Dorigo-Zetsma, J. W. et al. Immune status of health care workers to measles virus: evaluation of protective titers in four measles IgG ELIS. J. Clin. Virol. 69, 214–218 (2015).

Z.Q. Toh et al.

ACKNOWLEDGEMENTS
We thank the study participants and their families. We also thank Laboratory Services at the Royal Children’s Hospital, Parkville, Australia for performing the measles immunogenicity testing. This work was supported by the National Health and Medical Research Council of Australia (grant number 566792) and the Bill & Melinda Gates Foundation (grant number OPP1116833). GlaxoSmithKline Biologicals SA donated the doses of PCV10.

AUTHOR CONTRIBUTIONS
Z.Q.T. and P.V.L. did the analysis and wrote the initial draft of the manuscript. B.T., E.K.M., P.V.L., T.N.H., N.T.T. and D.Y.U. contributed to the study design. V.T.T.D. and K.B were involved in sample collection. L.A.H.D. contributed to the analysis and literature review. All authors contributed equally to the critical review of the manuscript and approved the final version.

COMPETING INTERESTS
All authors except Z.Q.T. and L.A.H.D. received salary support from grants from the National Health and Medical Research Council of Australia or the Bill & Melinda Gates Foundation. Non-financial support (in the form of PCV10 vaccine doses) was provided by GlaxoSmithKline Biologicals SA. Authors Z.Q.T. and L.A.H.D. report no potential conflicts.

ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/s41541-020-00225-z.

Correspondence and requests for materials should be addressed to P.V.L.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020
